| ACE2 | Angiotensin-Converting Enzyme 2 |
| ADHD | Attention-Deficit/Hyperactivity Disorder |
| Ang II | Angiotensin II |
| ARDS | Acute Respiratory Distress Syndrome |
| ASD | Autism Spectrum Disorder |
| BBB | Blood-Brain Barrier |
| CBD | Cannabidiol |
| CNS | Central Nervous System |
| COVID-19 | Coronavirus Disease 2019 |
| DPP4 | Dipeptidyl Peptidase 4 |
| EEG | Electroencephalography |
| E/I | Excitation/Inhibition |
| FFT | Fast Fourier Transform |
| fMRI | Functional Magnetic Resonance Imaging |
| GABA | Gamma-Aminobutyric Acid |
| GRDA | Generalized Rhythmic Delta Activity |
| ICU | Intensive Care Unit |
| MERS-CoV | Middle East Respiratory Syndrome Coronavirus |
| MRI | Magnetic Resonance Imaging |
| NAC | N-acetylcysteine |
| NCSE | Non-Convulsive Status Epilepticus |
| PASC | Post-Acute Sequelae of SARS-CoV-2 infection |
| PET | Positron Emission Tomography |
| QEEG | Quantitative Electroencephalography |
| RCT | Randomized Controlled Trial |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2 |
| SMR | Sensorimotor Rhythm |
| TBR | Theta/Beta Ratio |
| WHO | World Health Organization |